Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

Advances in immunotherapy have changed the therapeutic landscape of non-small cell lung cancer (NSCLC), extending overall survival over standard chemotherapy. However, by removing the protection against autoimmunity, immunotherapy can increase immune-related adverse events (irAEs). In addition, new...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixidor, Eduard, Sais, Elia, Vásquez, Carmen Amalia, Carbajal, Walter, Hernández, Alejandro, Sánchez, Gloria, Izquierdo, Angel, Verdura, Sara, Menéndez, Javier A., Bosch-Barrera, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152477/
https://www.ncbi.nlm.nih.gov/pubmed/30250648
http://dx.doi.org/10.18632/oncotarget.25984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152477/
https://www.ncbi.nlm.nih.gov/pubmed/30250648
http://dx.doi.org/10.18632/oncotarget.25984

Ejemplares similares